1. Academic Validation
  2. DSP30 enhances the immunosuppressive properties of mesenchymal stromal cells and protects their suppressive potential from lipopolysaccharide effects: A potential role of adenosine

DSP30 enhances the immunosuppressive properties of mesenchymal stromal cells and protects their suppressive potential from lipopolysaccharide effects: A potential role of adenosine

  • Cytotherapy. 2016 Jul;18(7):846-59. doi: 10.1016/j.jcyt.2016.04.004.
Bruno Sangiorgi 1 Helder Teixeira De Freitas 2 Josiane Lilian Dos Santos Schiavinato 1 Vitor Leão 1 Rodrigo Haddad 3 Maristela Delgado Orellana 2 Vitor Marcel Faça 4 Germano Aguiar Ferreira 4 Dimas Tadeu Covas 2 Marco Antônio Zago 1 Rodrigo Alexandre Panepucci 5
Affiliations

Affiliations

  • 1 Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, São Paulo, Brazil; Centro de Terapia Celular, Fundação Hemocentro de Ribeirão Preto, São Paulo, Brazil.
  • 2 Centro de Terapia Celular, Fundação Hemocentro de Ribeirão Preto, São Paulo, Brazil.
  • 3 Faculdade de Ceilândia, Universidade de Brasília, Brasília, Brazil.
  • 4 Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, São Paulo, Brazil.
  • 5 Universidade de São Paulo, Faculdade de Medicina de Ribeirão Preto, São Paulo, Brazil; Centro de Terapia Celular, Fundação Hemocentro de Ribeirão Preto, São Paulo, Brazil. Electronic address: rapane@gmail.com.
Abstract

Multipotent mesenchymal stromal cells (MSC) are imbued with an immunosuppressive phenotype that extends to several immune system cells. In this study, we evaluated how distinct Toll-like Receptor (TLR) agonists impact immunosuppressive properties of bone marrow (BM)-MSC and explored the potential mechanisms involved. We show that TLR4 stimulation by lipopolysaccharide (LPS) restricted the ability of MSC to suppress the proliferation of T lymphocytes, increasing the gene expression of interleukin (IL)-1β and IL-6. In contrast, stimulation of TLR9 by DSP30 induced proliferation and the suppressive potential of BM-MSC, coinciding with reducing tumor necrosis factor (TNF)-α expression, increased expression of transforming growth factor (TGF)-β1, increased percentages of BM-MSC double positive for the ectonucleotidases CD39+CD73+ and adenosine levels. Importantly, following simultaneous stimulation with LPS and DSP30, BM-MSC's ability to suppress T lymphocyte proliferation was comparable with that of non-stimulated BM-MSC levels. Moreover, stimulation of BM-MSC with LPS reduced significantly the gene expression levels, on co-cultured T lymphocyte, of IL-10 and interferon (IFN)γ, a cytokine with potential to enhance the immunosuppression mediated by MSC and ameliorate the clinical outcome of patients with graft-versus-host disease (GVHD). Altogether, our findings reiterate the harmful effects of LPS on MSC immunosuppression, besides indicating that DSP30 could provide a protective effect against LPS circulating in the blood of GVHD patients who receive BM-MSC infusions, ensuring a more predictable immunosuppressive effect. The novel effects and potential mechanisms following the stimulation of BM-MSC by DSP30 might impact their clinical use, by allowing the derivation of optimal "licensing" protocols for obtaining therapeutically efficient MSC.

Keywords

immunosuppression; inflammatory factors; multipotent mesenchymal stromal cells; toll-like receptors.

Figures
Products